Hyperosmolar Solution Effects in Guinea Pig Airways. III. Studies on the Identity of Epithelium-Derived Relaxing Factor in Isolated Perfused Trachea Using Pharmacological Agents
Public Domain
-
2004/01/01
-
Details
-
Personal Author:Dowdy JA ; Fedan, Jeffery S. ; Johnston RA ; Van Scott MR ; Wu DXY ; Dowdy JA ; Fedan, Jeffery S. ; Johnston RA ; Van Scott MR ; Wu DXY
-
Description:Hyperosmolar challenge of airway epithelium stimulates the release of epithelium-derived relaxing factor (EpDRF), but the identity of EpDRF is not known. We examined the effects of pharmacological agents on relaxant responses of methacholine (3 x 10(-7) M)-contracted guinea pig perfused trachea to mucosal hyperosmolar challenge using D-mannitol. Responses were inhibited by gossypol (5 x 10(-6) M), an agent with diverse actions, by the carbon monoxide (CO) scavenger hemoglobin (10(-6) M), and by the heme oxygenase (HO) inhibitor zinc (II) protoporphyrin IX (10(-4) M). The HO inhibitor chromium (III) mesoporphyrin IX (10(-4) M) was not inhibitory, and the HO activator heme-L-lysinate (3 x 10(-4) M) did not evoke relaxant responses. The CO donor tricarbonyldichlororuthenium (II) dimer (2.2 x 10(-4) M) elicited small relaxation responses. Other agents without an effect on responses included: apyrase, adenosine, 6-anilino-5,8-quinolinequinone (LY83583), proadifen, (E)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid (MK 571), diphenhydramine, glibenclamide, HgCl2, tetrodotoxin, nystatin, alpha-hemolysin, 8-bromoguanosine 3',5'-cyclic monophosphothioate, Rp-isomer, 12-O-tetradecanoylphorbol-13-acetate, cholera toxin, pertussis toxin, thapsigargin, nifedipine, Ca(2+)-free mucosal solution, hydrocortisone, and epidermal growth factor. Cytoskeleton inhibitors, includingerythro-9-(2-hydroxyl-3-nonyl)adenine, colchicine, nocodazole, latrunculin B, and cytochalasins B and D, had no effect on relaxation responses. The results suggest provisionally that a portion of EpDRF activity may be due to CO and that the release of EpDRF does not involve cytoskeletal reorganization. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:0022-3565
-
Document Type:
-
Genre:
-
Place as Subject:
-
CIO:
-
Division:
-
Topic:
-
Location:
-
Pages in Document:30-36
-
Volume:308
-
Issue:1
-
NIOSHTIC Number:nn:20024232
-
Citation:J Pharmacol Exp Ther 2004 Jan; 308(1):30-36
-
Contact Point Address:Dr. Jeffrey S. Fedan, Pathology and Physiology Research Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505-2888, USA
-
Email:jsf2@cdc.gov
-
Federal Fiscal Year:2004
-
NORA Priority Area:
-
Peer Reviewed:True
-
Source Full Name:Journal of Pharmacology and Experimental Therapeutics
-
Collection(s):
-
Main Document Checksum:urn:sha-512:5acb5ea0a3cd37b4e3ac5e1d3158cd9e892cf1e97311e1a69cfdd519ed2cfcce622ab6cc32fbfbf2df25181438233e10b0c77435f1cbdba149cdb05310f92c2b
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like